Sylvester Stallone TRT: How His Approach Compares to Similar Public Figures

What Stallone Has Actually Said About TRT

Stallone's disclosure is one of the most direct among public figures. In a 2008 interview with Time magazine, he stated that he uses human growth hormone and testosterone, calling HGH "fountain of youth stuff." That same year, Australian customs officers discovered testosterone and Jintropin (a brand of recombinant HGH) in his luggage, resulting in a guilty plea and a fine of AUD 10,600 under Australia's customs laws.

In later interviews and on social media, Stallone framed his use as medically supervised, not recreational. He has described working with physicians and emphasized that he views TRT as a quality-of-life measure rather than a performance-enhancement drug in the competitive-sports sense.

Why the Disclosure Matters Clinically

Stallone's openness is unusual. Most men, including public figures, do not volunteer hormone-therapy information. His statements have contributed to broader public awareness that hypogonadism is a diagnosable, treatable condition, not simply "getting old."

The Endocrine Society's 2018 Clinical Practice Guideline states: "We recommend making the diagnosis of androgen deficiency only in men with consistent symptoms and signs and unequivocally low serum testosterone concentrations." [1] Stallone has never released lab values publicly. His reported symptoms, fatigue, slower recovery, body-composition changes, are consistent with the clinical picture the guideline describes, but inferring a formal diagnosis from public statements alone is not possible.

The 2009 Legal Episode in Context

Australian law classifies testosterone as a Schedule 4 substance, requiring a local prescription. Importing it without one violates customs regulations regardless of whether a prescription exists in the home country. The incident does not indicate illicit recreational use; it reflects a regulatory gap between US and Australian prescription law. This distinction matters when comparing Stallone's situation to athletes sanctioned by anti-doping bodies, where the concern is competitive advantage, not personal medical care.

The Clinical Case for TRT in Men Over 50

Before comparing public figures, it helps to understand what the evidence actually supports for men in Stallone's age group.

Testosterone levels in men decline at roughly 1 to 2% per year after age 30, according to data from the Massachusetts Male Aging Study. [2] By the time a man reaches his mid-50s, a meaningful proportion will meet biochemical criteria for hypogonadism. A cross-sectional study by Mulligan et al. (2006, N=2,162) found that 38.7% of men over 45 presenting to primary care had a total testosterone below 300 ng/dL. [3]

What TRT Does to Body Composition

The body-composition effects Stallone has referenced are well-documented. A meta-analysis by Isidori et al. (2005, 29 randomized controlled trials, N=1,083) found that testosterone therapy produced a mean lean body mass increase of 1.6 kg and a fat mass reduction of 1.6 kg compared to placebo. [4] These are modest numbers. They do not explain the degree of muscularity Stallone maintained into his 70s on TRT alone, which strongly suggests additional factors including resistance training, nutrition, and potentially other compounds not publicly disclosed.

Cardiovascular Considerations

Cardiovascular risk is the most debated safety domain in TRT. The TRAVERSE trial (2023, N=5,204 hypogonadal men aged 45 to 80 with pre-existing or high risk for cardiovascular disease) found that testosterone therapy was non-inferior to placebo for major adverse cardiovascular events over a median follow-up of 33 months. [5] The FDA had previously required a cardiovascular warning label based on earlier observational data; the TRAVERSE results have shifted that conversation, though guidelines have not yet been fully updated to reflect the trial.

The Endocrine Society still recommends against TRT in men who have had a myocardial infarction or stroke within the previous 6 months, and advises hematocrit monitoring because testosterone increases red blood cell production. [1]

Comparing Stallone to Other Public Figures on TRT

Several other well-known men in the same age cohort have discussed hormone therapy publicly. The comparison below is based only on verifiable statements, interviews, or documented legal or medical events. Any inference is labeled as such.

Arnold Schwarzenegger

Schwarzenegger, born in 1947 and a lifelong competitive bodybuilder, has acknowledged in multiple interviews that he used anabolic steroids during his competitive years in the 1970s. He has also stated publicly that he uses testosterone replacement therapy as part of his current health regimen, describing it as medically supervised. Schwarzenegger underwent open-heart surgery in 1997 and again in 2018 for a valve replacement. His continued use of TRT in the context of structural heart disease places him in a higher-risk category than Stallone by the criteria of Endocrine Society guidance, though his physicians presumably weigh those risks directly. [1]

The key comparison point: both men entered their 50s with decades of high-dose anabolic steroid exposure from their professional careers. TRT for hypogonadal symptoms after prolonged supraphysiologic androgen use is a recognized clinical scenario. Long-term supraphysiologic testosterone use suppresses the hypothalamic-pituitary-gonadal (HPG) axis, and recovery of endogenous production may be incomplete, particularly in men who used androgens for more than a decade. [6]

Joe Rogan

Rogan, born in 1967, has discussed TRT extensively on The Joe Rogan Experience podcast, describing the protocol as physician-supervised and including testosterone cypionate injections, HGH, and other peptides. He has cited cognitive clarity, energy, and body composition as motivating factors. Rogan is roughly 20 years younger than Stallone, which places his use earlier in the hypogonadal age curve. Clinically, initiating TRT in a man in his early 50s with confirmed low testosterone and symptoms is within guideline-supported practice. [1]

Rogan's public commentary has had measurable cultural impact. Search volume for "TRT" on Google Trends increased substantially during periods of high-profile podcast discussions, suggesting his platform has driven awareness (and possibly self-diagnosis) in ways that Stallone's older interviews did not.

Rob Lowe

Lowe, born in 1964, has discussed hormone optimization in the context of general anti-aging medicine on various platforms, referencing a broader "wellness" protocol. His disclosures are less specific than Stallone's or Rogan's and do not confirm TRT use explicitly. Including him here as a comparison is therefore labeled as inference based on public statements about "hormone health" rather than confirmed TRT.

Nick Nolte

Nolte, born in 1941, was among the earlier public figures to discuss HGH use openly, doing so in a 2004 GQ profile. His case is relevant because it predates the mainstream TRT conversation and illustrates that hormone therapy in older men has been a practitioner-driven discussion for at least two decades before it entered popular culture.

TRT Protocols: What the Evidence Supports at This Age

Delivery Methods

The FDA has approved multiple delivery methods for testosterone: intramuscular injections (testosterone cypionate, testosterone enanthate), transdermal gels and patches, subcutaneous pellets, and a nasal gel (Natesto). [7] Stallone has not specified his delivery method publicly. Given his preference for injections discussed in fitness contexts, intramuscular or subcutaneous delivery is a reasonable inference, but it remains unconfirmed.

Testosterone cypionate 100 to 200 mg administered every 7 to 14 days intramuscularly is among the most common protocols in US clinical practice. Subcutaneous injections at lower doses (50 to 100 mg weekly) are increasingly used because they produce more stable serum levels and reduce injection-site discomfort. [8]

Monitoring Requirements

The Endocrine Society guideline specifies: "We suggest monitoring testosterone levels, hematocrit, and PSA 3 to 6 months after initiating treatment and then annually." [1] Hematocrit above 54% is listed as a threshold for dose reduction or temporary cessation.

PSA monitoring matters because testosterone therapy may stimulate subclinical prostate cancer growth. The guideline recommends against initiating TRT in men with prostate cancer, a palpable prostate nodule, or PSA above 4 ng/mL without urological evaluation. [1]

The HGH Component

Stallone's 2008 disclosure included HGH, not just testosterone. Human growth hormone is FDA-approved only for specific diagnoses including adult growth hormone deficiency confirmed by stimulation testing. [9] Prescribing it for general anti-aging or body-composition purposes is off-label and is not supported by current endocrinology guidelines. The Endocrine Society issued a position statement explicitly recommending against GH use in healthy older adults for anti-aging purposes. [10]

This distinction separates Stallone's disclosed regimen from a standard, guideline-concordant TRT protocol. Combining testosterone and HGH is sometimes practiced in longevity medicine clinics, but the evidence base for that combination in healthy aging men is not comparable to the evidence base for TRT in hypogonadism.

What Drives Public Figures Toward TRT: A Clinical Framework

Public figures in physically demanding careers share a specific clinical profile that may accelerate the hypogonadal timeline. Years of intense resistance training, repeated injury, caloric restriction for roles, and high psychological stress all influence the HPG axis. Cortisol elevation from chronic stress directly suppresses gonadotropin-releasing hormone pulsatility, reducing LH and FSH, which in turn reduces testicular testosterone output. [11]

For Stallone specifically, the physical demands of the Rocky and Rambo franchises across four decades represent an extreme example of occupational physical stress. The inference that his endogenous testosterone production may have been compromised earlier than average for his age group is clinically plausible, though it remains inference without lab data.

The framework for evaluating any public figure's TRT use should follow three questions. First: is there documented or credibly reported hypogonadal symptomatology? Second: is the use described as physician-supervised with monitoring? Third: does the disclosed regimen fall within approved indications or extend into off-label territory? Stallone scores affirmatively on the first two by his own statements and ambiguously on the third because of the HGH component.

Regulatory and Legal Context for TRT in the US

Testosterone is classified as a Schedule III controlled substance under the Controlled Substances Act. Prescribing it requires a legitimate physician-patient relationship and, per DEA guidance, a valid diagnosis. [12] The FDA approved testosterone for hypogonadism due to primary or secondary causes, and in 2015 revised its labeling to require cardiovascular risk language following early observational safety signals. [7]

Telehealth platforms now prescribe TRT after remote evaluation, which has increased accessibility. The DEA's 2023 proposed rules on telemedicine prescribing of controlled substances would have restricted this, but enforcement has been delayed pending final rulemaking. For patients like Stallone who use in-person physician relationships, none of these telehealth regulatory questions apply directly.

Does Stallone's Physique at 70+ Require More Than TRT?

This is the central question clinicians and fitness professionals ask. The honest clinical answer is yes, almost certainly.

Physiological testosterone replacement restores serum testosterone to the normal range: 300 to 1,000 ng/dL. [1] The upper end of that range, even if achieved consistently, does not produce the degree of hypertrophy visible in Stallone's film appearances in his late 60s and early 70s. DEXA-scan data from clinical TRT trials shows mean lean mass gains of 1.5 to 2.0 kg over 12 months. [4] The visual muscle mass differences between a TRT-treated 70-year-old and a natural 70-year-old are real but modest by the standards of what is visible on screen.

This does not mean Stallone is dishonest about his disclosures. It means his disclosures are likely incomplete, which is true of virtually every public figure in this category. Resistance training at a high volume with professional guidance, precise nutrition, and possibly additional compounds not publicly named all contribute. The clinical takeaway for patients is that TRT is not a substitute for resistance training, and resistance training amplifies TRT's body-composition benefits significantly. A 2016 meta-analysis by Bhasin et al. Confirmed that testosterone therapy combined with resistance exercise produced additive lean mass gains compared to either intervention alone. [13]

Clinical Takeaways for Men Over 50 Considering TRT

The Stallone comparison is useful for public awareness but should not drive individual clinical decisions. Men over 50 considering TRT should start with a morning total testosterone measurement (collected between 7 and 10 AM, when levels peak), followed by a repeat measurement on a separate day if the first result is below 300 ng/dL. [1]

Who Qualifies

The Endocrine Society guideline recommends TRT only for men with both biochemical confirmation of low testosterone and clinical symptoms, including reduced libido, fatigue, depressed mood, decreased bone density, or reduced lean mass. [1] A total testosterone above 400 ng/dL generally does not support a hypogonadism diagnosis even with symptoms, and prescribing TRT in that range is not guideline-supported.

What to Expect in the First 12 Months

Energy and libido improvements typically appear within 3 to 6 weeks of reaching therapeutic testosterone levels. Lean mass and fat mass changes require 3 to 6 months of consistent therapy and are substantially larger when combined with structured resistance training. Bone mineral density improvements require 12 to 24 months of treatment. [1]

When to Reconsider

Men with hematocrit above 50% at baseline, active prostate cancer, untreated severe obstructive sleep apnea, or a recent cardiac event should not initiate TRT without specialist evaluation. [1] A PSA rise of more than 1.4 ng/mL above baseline within 12 months of starting TRT warrants urological referral per guideline criteria.

The Endocrine Society's 2018 guideline remains the reference standard for these decisions. Men whose symptoms and lab values meet criteria should expect a morning total testosterone target of 400 to 700 ng/dL on therapy, not supraphysiologic levels, which distinguishes medical TRT from the anabolic use that characterized Stallone's competitive-era peers in professional bodybuilding.